ASH Meeting on Hematologic Malignancies

ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions

Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL...

The National Comprehensive Cancer Network’s guidelines for the management of non-bulky diffuse large B-cell lymphoma (DLBCL) recommend that, for patients with early-stage disease, shortening...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What would you recommend for a woman with...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

The Inaugural ASH Meeting on Hematologic Malignancies: A Discussion With the Co-Chairs

New clinical and biologic data within lymphoid and myeloid malignancies, including newly completed clinical trials, novel drugs, and insight into the genetic basis of these varied diseases is coming so fast and...

Age, Sex, Timing of Treatment Response Predict Avascular Necrosis in Children with ALL

Avascular necrosis (AVN), a disorder resulting from a temporary or permanent loss of blood supply to the bone, is one of the most serious...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat a patient with nodular...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.